
South West London Primary Care Flowchart for investigation and management of patients at risk of Osteoporosis and Fragility Fracture



Clinical risk factors for osteoporosis/fractures, not accommodated in FRAX®, which should trigger fracture risk assessment- from Table 4 NOGG Guidelines. Section 3: Fracture risk assessment and case finding NOGG

- Thoracic kyphosis, Height loss (> 4cm), Falls and Frailty
- Inflammatory disease: e.g., ankylosing spondylitis, other inflammatory arthritides, connective tissue diseases, systemic lupus erythematosus
- Endocrine disease: e.g., Type I and II diabetes mellitus, hyperparathyroidism, hyperthyroidism, hypogonadism, Cushing's disease/syndrome
- Haematological disorders/malignancy e.g., multiple myeloma, thalassaemia
- **Muscle disease**: e.g., myositis, myopathies and dystrophies, sarcopenia
- **Lung disease**: e.g., asthma, cystic fibrosis, chronic obstructive pulmonary disease
- HIV
- Neurological/ psychiatric disease e.g., Parkinson's disease and associated syndromes, multiple sclerosis, epilepsy, stroke, depression, dementia
- **Nutritional deficiencies**: calcium, vitamin D [note that vitamin D deficiency may contribute to fracture risk through undermineralisation of bone (osteomalacia) rather than osteoporosis]
- **Bariatric surgery** and other conditions associated with intestinal malabsorption
- **Medications, e.g.:**(Excess) **thyroid** hormone treatment (levothyroxine and/or liothyronine)
- Patients with **thyroid cancer** with suppressed TSH are at particular risk
- **Drugs affecting gonadal hormone** production -aromatase inhibitors (i.e letrazole/anastrazole) androgen deprivation therapy (i.e Zoladex<sup>®</sup>) medroxyprogesterone acetate (i.e Depo-Provera<sup>®</sup> starting <20 years or used after 35years), gonadotrophin hormone releasing agonists, gonadotrophin hormone receptor antagonists
- Some diabetes drugs (e.g., thiazolidinediones)
- Some **antiepileptics** (e.g., phenytoin and carbamazepine)
- Some immunosuppressants (tacrolimus/ciclosporin)

## Recommended baseline clinical investigations to consider for the investigation of osteoporosis/ fragility fractures:

- Clinical history
- Physical examination including measurement of height and assessment of thoracic kyphosis
- Consider x ray Thoracic/ lumbar spine if loss of height >4cm from baseline or clinical kyphosis
- Full blood cell count
- Erythrocyte sedimentation rate or C-reactive protein
- Serum calcium, albumin, creatinine, phosphate, alkaline phosphatase and liver transaminases -*Persistent low phosphate or alkaline phosphatase should not be overlooked as this can indicate underlying metabolic bone disease.*
- Serum 25-hydroxyvitamin D
- Thyroid function tests
- Myeloma screen -Serum electrophoresis, serum immunoglobulins and urine Bence Jones protein
- Consider checking Plasma parathyroid hormone (PTH) if raised serum calcium >2.6 mmol/L on 2 occasions
- Consider coeliac screen if suspicious of malabsorption
- For referral for very high-risk patients QRISK

## **Useful Resources:**

- <u>ROS Patient resources on treatments</u>
- <u>NOGG FAQs</u>
- Atypical (unusual) thigh bone fractures and drug treatments for osteoporosis
- Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis

Author: SWL Rheumatology Bone Health Network

Approved by: Integrated medicines optimisation committee (IMOC)

Approval Date: July 2024

Review Date: July 2026